An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL  by Kakadia, Purvi M. et al.
Contents lists available at ScienceDirect
Leukemia Research Reports
journal homepage: www.elsevier.com/locate/lrr
An ETV6-ABL1 fusion in a patient with chronic myeloproliferative
neoplasm: Initial response to Imatinib followed by rapid transformation
into ALL
Purvi M. Kakadiaa, Ralf Schmidmaierb, Andreas Völklb, Irene Schneiderc, Natalia Hukc,
Stephanie Schneiderc, Gerda Panznerd, Ulrike Neideld, Barbara Fritzd, Karsten Spiekermannc,
Stefan K. Bohlandera,⁎
a Department of Molecular Medicine and Pathology, The University of Auckland, Auckland, New Zealand
b Department of Internal Medicine, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München (LMU), Munich, Germany
c Laboratory for Leukemia Diagnostics, Department of Medicine III, University of Munich Hospital, Campus Grosshadern, Munich, Germany
d Center for Human Genetics, Philipps University, Marburg, Germany
A R T I C L E I N F O
Keywords:
ETV6/ABL1 fusion
CML
ALL
MRD assay
TKI treatment
A B S T R A C T
We report the case of a 26 year-old patient presenting with a persistent leukocytosis and CML-like marrow but
no evidence of a BCR/ABL1 fusion. Molecular cytogenetics revealed that a portion of the ETV6 locus was
inserted into the ABL1 locus. An ETV6/ABL1 fusion transcript could subsequently be conﬁrmed. The patient
was started on imatinib and went into complete cytomorphological remission. QRT-PCR measurements showed
a 4 log reduction of the ETV6/ABL1 fusion. 15 months later, the disease transformed into ALL and the patient
expired. Thus, an ETV6/ABL1 fusion positive MPN has the potential to transform very rapidly into ALL.
1. Introduction
The ETV6-ABL1 (TEL-ABL) fusion is a rare aberration found in a
range of haematologic malignancies. First described in 1995 [1], only
27 ETV6-ABL1-positive cases diagnosed with atypical chronic myeloid
leukemia (aCML), chronic myeloproliferative neoplasm (cMPN), acute
lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) have
been reported up to now [2–5]. The rarity of the ETV6-ABL1
rearrangement is thought to be due to the opposite transcriptional
orientations of the ETV6 and the ABL1 genes relative to the telomere-
centromere axis, which requires at least three DNA breaks to generate a
functional ETV6-ABL1 fusion gene [5]. Thus in most ETV6-ABL1-
positive cases, the fusion is generated as the result of complex, often
cryptic, chromosomal rearrangements. The frequent cryptic nature of
these rearrangements is likely to have resulted in underreporting of
ETV6-ABL1-positive cases. Due to breakpoint heterogeneity, two types
of ETV6-ABL1 fusion transcripts are found: the ‘type A’ transcript is a
fusion of the ﬁrst 4 ETV6 exons to the second exon of ABL1 and in the
‘type B’ transcript the ﬁrst 5 exons of ETV6 are fused to the second
exon of ABL1. ETV6-ABL1 activates similar cellular pathways like
BCR-ABL1. In vitro studies have shown that both fusion proteins lead
to the constitutive activation of the ABL1 tyrosine kinase [6]. Like BCR-
ABL1, ETV6-ABL1 is sensitive to ABL1 tyrosine kinase inhibitors [7,8].
Here, we report an ETV6-ABL1 fusion in a young female patient
with a myeloproliferative disorder, which rapidly transformed into an
acute lymphoblastic leukemia (ALL). The initial diagnostic screening
tests for a BCR-ABL fusion did not detect any sign of an ABL1
rearrangement. This case highlights the importance of a detailed
cytogenetic work-up in detecting the ETV6-ABL1 fusion and the
necessity of careful minimal residual disease monitoring as well as
the danger of rapid transformation of ETV6-ABL1 positive MPNs into
ALL.
2. Materials and methods
2.1. Cytogenetic analysis
Chromosomes were prepared from short-term bone marrow cul-
tures according to standard protocols. For the conﬁrmation of the
cytogenetic ﬁndings, ﬂuorescence in situ hybridization (FISH) using
commercially available FISH probes was performed following standard
protocols (Abott).
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2.2. RT-PCR and sequencing
mRNA was isolated from mononuclear cells using the MagnaPure
(Roche) kits according to the manufacturer's protocols. Whole RNA
was isolated from the mononucleated cells from bone marrow or
peripheral blood samples using the RNeasy mini kit (QIAGEN). The
RNA was then reverse transcribed to generate cDNA using the
Superscript™ III reverse transcriptase (Invitrogen). As a part of the
routine diagnostics work up, a reverse transcriptase (RT)-PCR with
primers speciﬁc for the BCR-ABL1 p210 and p190 fusion transcripts
was performed [9]. RT-PCR analysis with the following primers
was performed for the detection of the ETV6-ABL1 fusion: ETV6-
ABL1-(E4/E2)_F (5′- AAAGCTCTCCTGCTGCTGAC-3′) corresponding
to exon 3 of ETV6 and ETV6-ABL1-(E4/E2)_R (5′- TGTTA
TCTCCACTGGCCACA −3′) corresponding to exon 2 of ABL1 were
used for the detection of the ‘type A’ ETV6-ABL1 fusion transcript.
Additionally, primers ETV6-ABL1-(E5/E2)_F (5′-AAG CCC ATC AAC
CTC TCT CA-3′) from exon 5 of ETV6 and ETV6-ABL1-(E5/E2)_R
(5′-ACA CCA TTC CCC ATT GTG AT-3′) from exon 2 of ABL1
were used for the detection of the ‘type B’ ETV6-ABL1 fusion
transcript. To detect the reciprocal ABL1 (exon1a/1b)/ ETV6
(exon6) fusion transcript the primers ABL1a_ex1a_F
(5′-GTTGGAGATCTGCCTGAAGC−3′), ABL1b_ex1b_F (5′-GGAGC
AGGGAAGAAGGAATC-3′) and ETV6_WT_Ex7_R (5′-TCCT
GGCTCCTTCCTGATAA-3′) were used. To identify an ABL1-ETV6
fusion transcript, which might be generated by an insertion of the 5′
portion of ETV6 between the exons Ex1a/1b and exon 2 of ABL1,
primers ABL1a_ex1a_F, ABL1b_ex1b_F and ETV6_Ex4_R (5′-
GGGTGGAAGAATGGTGAAAA-3′) were used. For the mutation detec-
tion in the ETV6 transcript, the whole ETV6 transcript was ampliﬁed in
four overlapping fragments using the primers, ETV6_WT_F1_F
(5′-GGGAGAGGAAAGGAAAGTGG-3′), ETV6_WT_F1_R (5’-ACC
TCCGGCTGTGT GTGTAT-3’), ETV6_WT__F2_F (5′-CAG
CATATTCTGAAGCAGAGGA-3′), ETV6_WT_F2_R (5′-AGGA
TCAGAGGGTGCATGAT-3′), ETV6_WT__F3_F (5′-CCCAT
GGAGAATAATCACTGC-3′), ETV6_WT_F3_R (5′-GCAGGGC
TCTGGA CATTTT-3′), ETV6_WT__F4_F (5′-CGACTG
TGGGGAAACCAT AA-3′) and ETV6_WT_F4_R (5′-AAGT
GTCCCTGCCATTTCTG-3′). The RT-PCR products were sequenced
with the BigDye terminator v1.1 cycle sequencing kit on an ABI
PRISM 310 Genetic analyzer (Applied Biosystems, USA).
2.3. Minimal residual disease (MRD) monitoring
For the monitoring of the minimal residual disease, the level of the
ETV6-ABL1 fusion transcript was estimated by reverse transcription
quantitative real-time PCR (RQ-PCR). A 150 bp fragment spanning the
breakpoint of the ETV6-ABL1 fusion transcript was ampliﬁed on a
Light-Cycler MxPro3005 instrument (Stratagene) using the primers
qPCR_ETV6-ABL1(E5/E2)_F1 (5′-AAGCCCATCAACCTCTCTCA-3′) and
qPCR_ETV6-ABL1(E5/E2)_R1 (5′-ACC CTGAGGCTCAAAGTCAG-3′).
As a reference transcript, a region from the 5’ portion of ABL1 that is
only contained in the non-rearranged ABL1b isoform was ampliﬁed using
the primers ABL1_qPCR_F (5′-CAGGGAAGAAGGAATCATCG-3′) and
ABL1_qPCR_R (5′-GTTGGGGTCATT TTCACTGG-3′). The ETV6-ABL1
fusion transcript was normalized to the ABL1 transcript (ETV6-ABL1/
ABL1 ratio) in the pre- and post treatment samples. Finally, the normal-
ized level of the ETV6-ABL1 transcript at diagnosis was set as 1 and the
ETV6-ABL1 fusion transcript levels at the follow-up time points were
expressed relative to the level at the initial diagnosis.
3. Results
A 26-year-old women with psoriasis was clinically evaluated with
suspicion of psoriatic arthritis of the shoulder. Her psoriasis was not
severe and well controlled with stress avoidance and mild topical
ointments. Routine blood count showed an increased WBC of 40,000/
µl. An RT-PCR assay for a BCR-ABL fusion from peripheral blood was
negative. Although her shoulder pain resolved, the leukocytosis per-
sisted. A bone marrow biopsy in December 2012 showed a packed
marrow with trilineage hyperplasia and an eosinophilia of 20–30%.
The neutrophils and eosinophils showed markedly hypersegmented
nuclei. The ﬁndings were compatible with a myeloproliferative disease.
An interphase FISH analysis with BCR-ABL1-DCDF (dual colour
dual fusion) probes (Abbott) showed a normal signal pattern. In
addition, an RT-PCR screen with primers speciﬁc for the BCR-ABL1
p210 and p190 fusion transcripts and a JAK2V617F mutation analysis
were both negative. Chromosomal analysis of the bone marrow cultures
revealed a 46, XX,t(10;12)(q24;p13) karyotype in 5 of 10 metaphases.
The remaining metaphase had a normal karyotype (46, XX,t(10;12)
(q24;p13)[5]/46, XX[5]). Whole chromosome painting probes (WCP)
speciﬁc for chromosomes 10 and 12 were used to conﬁrm the t(10;12)
translocation. As band 12p13 was involved in the rearrangement, we
assessed the status of the ETV6 locus with an ETV6 break apart probe
(Dako). This analysis detected a break in one of the ETV6 loci.
Interestingly, instead of on chromosome 10, the probe corresponding
to the 5’ genomic portion of ETV6 hybridized, quite unexpectedly, to
9q34 suggesting an involvement of the ABL1 locus. However, when we
repeated the BCR/ABL DCDF FISH analysis on metaphase chromo-
somes there was no alteration of the ABL1 loci visible. Only a
combination of the BCR-ABL1-DCDF and an ETV6/AML1-ES (extra
signal) dual colour probes (Fig. 1A) revealed a co-localization of the 5’
ETV6 genomic region with the ABL1 locus (Fig. 1B). These ﬁndings
suggested the presence of an ETV6-ABL1 rearrangement. RT-PCR
using ETV6-ABL1 fusion transcript-speciﬁc primers indeed detected a
‘type B’ ETV6-ABL1 fusion transcript, which results from the fusion of
the ﬁrst 5 exons of ETV6 to exon 2 of ABL1. Sequence analysis of the
RT-PCR product conﬁrmed the presence of the ‘type B’ – ETV6-ABL1
fusion transcript, showing an in-frame fusion between exon 5 of ETV6
and exon 2 of ABL1 (Fig. 1C). These results suggested that an insertion
of the 5′ portion of the ETV6 locus up to ETV6 exon 5 into the ABL1
locus had occurred. We also performed a PCR experiment to detect the
reciprocal ABL1(exon1a/1b)/ETV6(exon6) fusion and a more 5′ fusion
which might result from the insertion (ABL1(exon1a/1b)/
ETV6(exon2/3/4)). Neither the reciprocal ABL1(exon1a/1b)/
ETV6(exon6) nor evidence for an ABL1(exon1a/1b)/ETV6(exon2/3/
4) fusion, as would be expected from an insertion, were found.
There is increasing evidence that ETV6 plays the role of a tumor
suppressor gene because the non-rearranged ETV6 allele is frequently
deleted in childhood ALL cases with an ETV6/RUNX1 fusion [6,10,11]
and ETV6 point mutations have also been described in hematological
malignancies [12]. In addition, ETV6mutations have been identiﬁed in
familial leukemia cases [13]. Therefore, we sequenced the complete
coding region of ETV6 in our patient. This analysis did not reveal a
mutation (data not shown).
Based on the detection of the ETV6-ABL1 fusion transcript, oﬀ-
label, evidence-based Imatinib therapy (400 mg/d) was commenced
[3,5,14–19]. She showed a complete normalization of her blood counts
after 4 weeks. We developed a quantitative real time PCR assay (RQ-
PCR) for the ETV6-ABL1 fusion transcript. Our minimal residual
disease (MRD) monitoring revealed a 4 Log10 fold reduction in the
levels of the ETV6-ABL1 fusion transcript over a period of 11 months.
There was a moderate increase of MRD levels of about 1.5 Log10 fold 6
months later (Fig. 1D).
The patient presented 3 weeks later at our emergency department
because of painful swelling of the right leg in combination with
shortness of breath for 1 week. Duplex ultrasonography revealed deep
vein thrombosis and CT angiography revealed pulmonary emboli. Full
blood count showed 30,000 white blood cells per µl with 48% lymphoid
blast cells (normal haematocrit, 80,000 platelets/µl). A bone marrow
aspirate showed 70% lymphoid blasts. At this time, the ETV6-ABL1
transcript levels were about three times the level at initial presentation.
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Sequencing of the tyrosine kinase domain of the ETV6-ABL1 fusion
transcript did not reveal any mutations. These results indicate that the
ALL clone was ETV6-ABL1 positive. At this time the cytogenetic
analysis showed 46, XX, der(9)t(9;12)(q34;p13), del(10)(q24),
del(11)(q23), der(12)t(10;12)(q24;p13)[8]/46, XX[2].
The patient was started on standard induction chemotherapy
according to the German Multicenter Study Group on Adult Acute
Lymphoblastic Leukemia (GMALL) and an allogeneic stem cell donor
search was initiated due to the high risk condition. Five days after start
of the treatment, the patient fell into a coma due to a cerebral sinus
thrombosis with secondary haemorrhage. Despite repeated neurosur-
gical interventions the patient died two weeks later.
4. Discussion
The ETV6 gene on the short arm of chromosome 12 is transcribed
from the telomere to the centromere, whereas ABL1 is transcribed
from the centromere to the telomere on the long arm of chromosome 9.
The diﬀerent transcriptional orientations of ETV6 and ABL1 are most
likely the reason for the rarity and complexity of ETV6-ABL1 rearran-
gements. In most of the reported ETV6-ABL1 cases, these so-called
cryptic rearrangements were not detected by conventional cytogenetics.
FISH analyses showed that the ETV6-ABL1 fusion resulted either from
an insertion of the 3′ region of the ABL1 gene into the ETV6 locus or an
insertion of the 5′ region of the ETV6 gene within the ABL1 gene locus.
FISH screening for the BCR-ABL1 rearrangement is part of the routine
diagnostic work-ups for MPD (CML and MPNs) and ALL. Depending
on the type of FISH probe used, this assay also allows the detection of
unusual rearrangements at the BCR and ABL1 loci. Therefore, cryptic
ETV6-ABL1 rearrangements, resulting from an insertion of the 3’ ABL1
region within the ETV6 locus, can be detected during the routine
diagnostic work-up as an additional or split ABL1 signal. However, the
ETV6-ABL1 fusions resulting from an insertion of the 5’ ETV6 region
within the ABL1 locus will be overlooked, unless an ETV6 rearrange-
ment speciﬁc FISH assay is performed. In cases with a t(9;12;Var), the
involvement of 9q34 or 12p13 is an indication that an ETV6-ABL1
rearrangement might be present, which can then be conﬁrmed by
speciﬁc FISH assays and ETV6-ABL1 fusion speciﬁc RT-PCR.
However, cases like the one present here, pose a problem since our
initial BCR-ABL1 FISH assay was completely normal and the results of
Fig. 1. Detection of the ETV6-ABL1 fusion: A. Schematic diagram of commercial BCR-ABL1-DCDF and the RUNX1-ETV6-ES FISH probe designs. B. Co-hybridization of the BCR-
ABL1-DCDF and the RUNX1-ETV6-ES FISH probes on the metaphase chromosomes preparation from the patient sample: RUNX1 and BCR locus were intact. As predicted, one of the
green signals for ETV6-5′ region was observed co-localized with one of the ABL1 loci on chromosome 9 (white arrow). C. Electropherogram of the sequence spanning the breakpoint
conﬁrming an in-frame fusion between ETV6 exon 5 and ABL1 exon2. (upper panel) and fusion transcript sequence and the corresponding wild type sequences including the amino acid
sequence (lower panel). The vertical grey line indicates the position of the breakpoint. D. Overview of the ETV6-ABL1 fusion transcript level during the course of treatment with
reference to that at the diagnosis. Imatinib treatment was started 2 months after the diagnosis time point. MRD: minimal residual disease: * Relative Expression of ETV6/ABL1: The
expression level of ETV6/ABL1 at the time of diagnosis is set to 1. ETV6-ABL1 expression levels are normalized to the expression levels of ABL1. Relative Expression=2exp(Δ CtETV6/
ABL1(follow-up)-Δ CtETV6/ABL1 (diagnosis)).
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our initial cytogenetics analysis did not indicate an involvement of the
ABL1 locus either. The only hint came from the chromosomal
rearrangement involving band p13 of chromosome 12 on chromosome
9. With ETV6-ABL1 being a rather rare entity, FISH probes speciﬁc for
the detection of the ETV6-ABL1 fusion are not commercially available.
However, a FISH assay using a mixture of the standard FISH probes
for the BCR-ABL1 and the ETV6-RUNX1 fusions on the metaphase
chromosomes can detect and characterize even cryptic and rare ETV6-
ABL1 rearrangements. Recently, multiplex RT-PCR assays have been
shown to be eﬃcient tools for the detection of a wide range of leukemia
speciﬁc fusion transcripts. Several ETV6-ABL1 cases were detected by
such multiplex RT-PCR approach [2,4]. Table 1 gives an overview of
the ETV6-ABL1 positive cases described in the literature so far. This
table is an up-date and extension of the table of Zuna et al. [5].
The ETV6-ABL1 fusion has been reported as a poor prognostic
factor when found in acute leukemia (AML and ALL) and MDS. The
prognostic signiﬁcance of an ETV6/ABL1 chronic myeloproliferative
neoplasm is less clear due to the paucity of cases and the lack of
controlled clinical trials [5]. There is a signiﬁcant overlap of molecular
targets of ETV6-ABL1 with those of BCR-ABL1, and the ETV6-ABL1
fusion protein triggers similar oncogenic cascades like the BCR-ABL1
fusion protein [3,10]. Similar to BCR-ABL1 positive cells, ETV6-ABL1
positive cells show in-vitro sensitivity to the tyrosine kinase inhibitor
Imatinib [7,8]. Several authors have also reported a transient [5,14–
16] or prolonged [3,17–19] response to Imatinib or second generation
tyrosine kinase inhibitor treatment in ETV6-ABL1-positive neoplasms,
with the response to TKI being better and longer in ETV6-ABL1-
positive myeloproliferative neoplasms. Thus, the detection of a cryptic
ETV6-ABL1 rearrangement has a signiﬁcant impact on patient care,
especially in the case of chronic myeloproliferative neoplasms or
chronic myeloid leukemia like phenotypes. However, there are only
reports of 8 ETV6-ABL1 positive patients having been treated with
Imatinib for various diseases (CML, AML, MPN, ALL) according to
diﬀerent therapy protocols [3,5,14–21]. Of the 7 patients with ETV6-
Table 1
Review of reported ETV6-ABL1 positive cases till date (adapted from [5]).
Case
number
Diagnosisa Gender Age at
diagnosis
(years)b
TKIc
treatment
Outcomed Eosinophilia Type of
transcript
Reference Cytogenetics:
detailed work-up
1 ALL F 1 (22 M) No Died n.r. A [1] n.r.
2 AML-M6 M 81 No Died n.r. B [6] n.r.
3 CML (atypical) n.r. 49 No Died Yes B [22] n.r.
4 CML M 32 No CR ( > 3Y) Yes B [23] Yes: Group B
5 CML M 59 No Died Yes A, B [24] n.r.
6 ALL (T-lineage) M 4 No Died Yes A, B [24] n.r.
7 AML-M6 (or
CML-MBC? )
M 38 Yes Died n.r. A, B [16] Yes: Group A
8 CML M 53 No CR ( > 6Y) Yes A, B [25] n.d. (NK, B/FISH-)
9 CML F 44 No CR ( > 6 M) Yes n.r. [26] Yes: Group B
10 AML-M2 M 29 No CR ( > 20 M
post HSCT)
Yes A [27] Yes: Group A
11 AML-M1(after
RAEB)
M 48 No Died Yes B [27] Yes: Group B
12 CML-MBC M 36 Yes Died Yes B [14] n.a.
13 CML-LBC M 72 Yes CR ( > 12 M) n.r. B [19] Yes: Group A
14 cMPN - myeloid
sarcoma
F 65 No Died Yes A, B [28] Yes: Group A
15 cMPN M 57 No CR ( > 15Y) Yes n.r. [29] Yes: Group A
16 ALL M 30 n.r. Died n.r. A, B [30] Yes: Group A
17 CML F 24 Yes CR ( > 7 M) Yes Eo: 3920/µl
(4%)
A, B [17] Yes: Group C
18 cMPN F 61 Yes CR ( > 3Y) Yes n.r. [18] Yes: Group A
19 CML (atypical) M 79 Yes Died Yes Eo: 2110/µl
(6%)
n.r. [15] Yes: Group A
20 ALL F 33 n.r. Died No A, B [5] Yes: Group A
21 ALL M 5 No CR ( > 24 M) Yes A, B [5] Yes: Group A
22 ALL M 0 (8 M) Yes Died No A, B [5] Yes: Group B
23 ALL F 8 Yes CR( > 10 M) n.r. A, B [21] Yes: Group A
24 aCML M 36 Yes CR ( > 5Y) Eo: 1650/µl (3%) n.r. [3] Yes: Group A
25 B-ALL M 58 No Died n.r. n.r. [4] n.r. except t(9;12) +
add abn
26 B-ALL F 49 No HSCTe n.r. n.r. [4] n.r. except 46, XX, t
(9;12)(q34;p13)[20]
27 AML M 52 No Died Yes B [2] n.r. except 46, XY[20]
28 B-ALL F 25 No CR ( < 15 M) No A, B [2] Yes: Group A
29 aCML F 52 Yes CR ( > 12 M) Yes A, B [20] Yes: Group B
30 MPN - > ALL F 26 Yes CR (18 M), Yes B This case Yes: Group B
n.r., not reported.
Group A: BCR-ABL1- FISH screen: BCR-ABL1 negative, ABL1 split: 12 cases (AML, ALL, MPN);
ETV6-ABL1 fusion on der(12)(p13): 10 cases (AML, ALL, MPN), ETV6-ABL1 fusion on a third chromosome: 2 cases (AML, CML-LBC).
Group B: BCR-ABL1- FISH screen: BCR-ABL1 negative, ABL1 not split, ETV6 rearranged. ETV6-ABL1 fusion on der(9)(q34): 4 cases (AML, ALL, MPN).
Group C: BCR-ABL1- FISH screen: BCR-ABL1 negative, ABL1 not split, but ASS deleted (5′ ABL1), 3 signals for ETV6. Duplication of 5′ETV6 and insertion of 5′ETV6 in der(9)(q34)
resulting in ETV6-ABL1 fusion: 1 case (CML).
a Diagnosis: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; LBC, lymphoid blast crisis; MBC, myeloid blast crisis; cMPN,
chronic myeloproliferative neoplasm; RAEB, refractory anemia with excess blasts.
b Age at diagnosis: In the two youngest patients also the age at diagnosis in months is shown in parentheses.
c TKI treatment: TKI, tyrosine-kinase inhibitors.
d Outcome: CR, complete remission; HSCT, stem cell transplantation, HSCT e: Hematopoietic stemcell transplantation without hematological or molecular CR
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ABL1-positive CML or MPN, who received TKI treatment, 5 re-
sponded, 4 with a prolonged remission. In contrast, of the 2 patients
with an ETV6/ABL1 positive AML or ALL, who received TKI treatment,
none responded with a longer remission duration (Table 1). However,
the eﬃcacy of Imatinib and second generation TKIs as well as the
optimal treatment schedule for ETV6-ABL1 positive hematological
malignancies still needs to be determined.
This case illustrates the importance of a careful cytogenetic work-up
for patients with a myeloproliferative neoplasm. If a patient can be
treated with a tyrosine kinase inhibitor instead of chemotherapy, a
signiﬁcant improvement in his/her quality of life and survival can be
achieved. The beneﬁts of long term TKI treatment in young patients
compared to a potentially curative bone marrow transplant need to be
carefully assessed. In this situation, careful MRD monitoring is
warranted. However despite good response to TKI, even tight MRD
monitoring was not able to predict the rapid transformation from a
myeloproliferative neoplasm into an acute lymphoblastic leukemia in
our patient. Additionally, the clinical presentation of the secondary
ETV6/ABL-positive ALL in our case was associated with a fatal
paraneoplastic thrombophilic syndrome. We can only speculate as to
what caused this rapid transformation from a relatively benign
myeloproliferative neoplasm to an aggressive ALL. It is known from
cytogenetic studies of CML in blast crisis that additional chromosomal
abnormalities arise at blast crisis (e.g. an additional copies of the
Philadelphia chromosome). This indicates that additional genetic
changes, either additional chromosomal abnormalities or point muta-
tions, are most likely responsible for disease transformation. Also in
our patient, chromosomal analysis showed that, in addition to the
rearrangements aﬀecting chromosomes 9, 10, and 12 found at pre-
sentation, there were additional changes on chromosome 11 in the ALL
clone. It is also highly likely that more detailed genomic analyses like
exome sequencing, SNP array CGH etc., would detect additional driver
mutations or deletion in genes previously shown to be aﬀected in
ETV6-ABL1-positive ALL like CDKN2A/B and IKZF1 [31] as well as
cryptic chromothripsis events [32]. To the best of our knowledge, this is
the ﬁrst description of an ETV6-ABL1-positive myeloid neoplasm that
transformed into an ALL. Therefore, ETV6-ABL1 positive patients,
even with a myeloid phenotype and CML-like clinical course, should be
viewed as high risk patients.
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